
Circular : 31.01.2011 |
1. WIPO (World Intellectual Property Organization)
Matter: In response to the letter from the Department of Pharmaceuticals,
following comments have been sent to Mr. B.K. Singh, Director Department
of Pharmaceuticals on the subject:
“This has reference to the meeting in your esteemed office on 20th instant on the subject cited above. The views of this confederation in this matter are as under: The European Union is lobbying hard at the Government level for inclusion of certain IPR related clauses and amendment of Indian patenting standards. E.U. wants India to define the period for data exclusivity and Supplementary Protection Certificate ( for 5 years from the date of expiry of patent). These demands, if accepted will hurt the Indian Pharmaceutical Industry most. This will result in ever greening of patents which is being opposed by all the developing countries. It will also delay the entry of indigenous generics after expiry of the patent. Further, their demand that the data exclusivity shall not be restricted to New Chemical Entities only but shall also be extended to other pharmaceutical products will hurt the R&D efforts of Indian Pharmaceutical Industry. These two factors in combination will dilute the Government’s ability to invoke compulsory licensing. It may also be noted that the consignments of genuine Indian generics have been confiscated and in spite of best efforts, the problem has not been resolved so far. We hope the views of this confederation will be taken in to consideration in your note to the Ministry of Commerce.” 2. FDI (Foreign Direct Investment) in Drugs & Pharmaceutical Industry: In response to a call from the Department of Pharmaceuticals, Ministry of Chemicals & Fertilizers, the views of CIPI in this matter has been forwarded to the Ministry as under: “In the past some of the leading Indian pharmaceutical companies have been acquired by multinational companies taking advantage of the present policy of the Department of Industrial Policy and Promotion, Government of India which permits 100% direct foreign investment in this sector through automatic route. This route does not require any prior permission of the Government by the target company or the acquirer. In the present scenario, after completing the deal, only intimation is required to be filed with the Reserve Bank of India. The MNCs probably have the following short term and long term objectives in such deals: 1. To have an access to cheap Indian manpower cost, In long term, this will result in shrinkage in the availability of the cheap generic products, reduced competitiveness in the pharmaceutical sector and higher cost to the patients. In our views this may be curtailed in the following manner without hurting the image of the Country: 1. 100 % FDI when introduced long back was intended
for bringing new technology to this sector by MNCs. 3. Simplification of export related procedures by DGFT:
Mr. Anup K. Pujari, Director General of Foreign Trade has stated that
his office is working on a scheme / system where paper work relating
to advance licensing, export promotion and capital goods licenses will
be reduced drastically. The proposed system will work on trust –based
self certification by the stake holders duly certified by a chartered
accountant on the basis of which the Department will act and take decisions.
A dialogue is taking place with the stake holders on this subject and
CIPI has also requested to be called so to understand the proposed system
and to express its views. 5.Black money stashed away in Swiss Banks ( FE Editorial
dated 26.01.2011): |
This Site is developed and maintained by Prashant
H. Pandya
Site updated on
31 January, 2011 11:06 PM
© Confederation of Indian
Pharmaceutical Industry (ssi)(Regd)